NewView Capital Partners I LLC decreased its position in 23andMe Holding Co. (NASDAQ:ME - Free Report) by 95.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 972,785 shares of the company's stock after selling 18,482,896 shares during the quarter. 23andMe makes up 8.8% of NewView Capital Partners I LLC's portfolio, making the stock its 2nd biggest holding. NewView Capital Partners I LLC owned 3.72% of 23andMe worth $3,162,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in ME. Vanguard Personalized Indexing Management LLC grew its position in shares of 23andMe by 410.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company's stock valued at $35,000 after acquiring an additional 71,204 shares during the period. Point72 DIFC Ltd purchased a new position in 23andMe during the second quarter valued at $43,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in 23andMe during the second quarter valued at about $203,000. AQR Capital Management LLC increased its position in 23andMe by 145.8% in the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company's stock worth $174,000 after buying an additional 263,468 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of 23andMe in the third quarter worth about $805,000. 36.10% of the stock is currently owned by institutional investors.
23andMe Stock Up 5.9 %
NASDAQ:ME traded up $0.20 on Thursday, reaching $3.61. 201,644 shares of the company's stock traded hands, compared to its average volume of 214,054. The stock has a 50-day simple moving average of $3.54 and a 200-day simple moving average of $5.71. 23andMe Holding Co. has a 12 month low of $2.65 and a 12 month high of $16.52. The firm has a market cap of $94.29 million, a PE ratio of -0.14 and a beta of 1.14.
23andMe (NASDAQ:ME - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%. The business had revenue of $44.07 million for the quarter, compared to the consensus estimate of $50.30 million.
23andMe Profile
(
Free Report)
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Featured Articles
Before you consider 23andMe, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 23andMe wasn't on the list.
While 23andMe currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.